Fact-checked by the Peptide Authority Editorial Board · Last reviewed: 2026-03-13
What Is Survodutide? Benefits, Research & Safety
A dual glucagon/GLP-1 receptor agonist under development by Boehringer Ingelheim, researched for its potential in weight management, metabolic health, and non-alcoholic steatohepatitis (NASH).
Also known as:
BI 456906
NN9838
Educational Content Only: This page provides research-based information for educational purposes. Survodutide is not an approved medicine. This is not medical advice. Always consult a qualified healthcare professional.
Quick Facts
Category
Fat Loss & Metabolic
Half-Life
Approximately 60-70 hours, supporting once-weekly dosing based on clinical pharmacokinetic data
UK Status
Not approved by the MHRA. Currently an investigational compound in Phase 3 clinical trials.
EU Status
Not authorised by the European Medicines Agency. Phase 3 clinical development ongoing.
Overview
Survodutide (BI 456906) is an investigational dual agonist peptide that targets both the glucagon receptor (GCGR) and the glucagon-like peptide-1 receptor (GLP-1R). Developed through a collaboration between Boehringer Ingelheim and Zealand Pharma, survodutide represents a novel approach to treating obesity and metabolic liver disease by harnessing the complementary actions of two key metabolic hormones.
Unlike pure GLP-1 receptor agonists such as semaglutide, survodutide's dual mechanism is designed to leverage glucagon's ability to increase energy expenditure and promote hepatic lipid oxidation alongside GLP-1's well-established effects on appetite suppression and glucose homeostasis. This combination may offer advantages in both weight reduction and the resolution of liver fat accumulation.
Clinical trials have demonstrated substantial weight loss in participants receiving survodutide, with some studies reporting reductions exceeding 18% of body weight. The compound has also shown promising results in reducing liver fat content, positioning it as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as NASH.
Survodutide is currently in Phase 3 clinical development and is not approved for human use by any regulatory authority including the MHRA or EMA. All information presented here is for educational purposes based on published research data.
Discovery & History
Survodutide was developed through a strategic partnership between Boehringer Ingelheim, one of the world's largest pharmaceutical companies, and Zealand Pharma, a Danish biotechnology company specialising in peptide therapeutics. The collaboration brought together Zealand Pharma's expertise in peptide engineering with Boehringer Ingelheim's extensive clinical development capabilities.
The concept of dual glucagon/GLP-1 receptor agonism emerged from growing scientific understanding that glucagon, traditionally viewed primarily as a counter-regulatory hormone to insulin, plays important roles in energy expenditure, lipid metabolism, and amino acid handling. Researchers hypothesised that carefully balancing glucagon receptor activation with GLP-1 receptor agonism could produce superior metabolic outcomes compared to targeting either receptor alone.
Zealand Pharma designed the survodutide molecule using their proprietary peptide chemistry platform, optimising the ratio of glucagon to GLP-1 receptor activity to maximise metabolic benefits whilst mitigating the hyperglycaemic effects of glucagon through concurrent GLP-1-mediated insulin secretion.
The compound entered Phase 1 clinical trials around 2019, with initial dose-finding studies establishing its pharmacokinetic profile and preliminary safety data. Promising early results led to rapid progression into Phase 2 trials, including studies in both obesity and NASH/MASH populations. By 2023, the compound had advanced into Phase 3 clinical development, reflecting the strength of the clinical data generated in earlier trials.
Mechanism of Action
Survodutide exerts its metabolic effects through simultaneous activation of two distinct but complementary receptor systems, creating a synergistic approach to weight management and metabolic improvement.
**GLP-1 Receptor Agonism**
The GLP-1 receptor component of survodutide's action mirrors the mechanisms employed by established GLP-1 receptor agonists. Activation of GLP-1 receptors in the pancreas stimulates glucose-dependent insulin secretion, helping to maintain glycaemic control. In the central nervous system, GLP-1 receptor activation in the hypothalamus and brainstem reduces appetite and promotes satiety, leading to decreased caloric intake. GLP-1 signalling also slows gastric emptying, contributing to prolonged feelings of fullness after meals.
**Glucagon Receptor Agonism**
The glucagon receptor component distinguishes survodutide from pure GLP-1 agonists. Glucagon receptor activation in the liver stimulates hepatic lipid oxidation and reduces de novo lipogenesis, potentially driving significant reductions in liver fat content. This hepatic effect is particularly relevant for patients with MASH/NASH. Glucagon also increases energy expenditure through thermogenic mechanisms, including activation of brown adipose tissue and enhancement of resting metabolic rate. Additionally, glucagon promotes amino acid catabolism and may influence body composition by supporting the maintenance of lean mass during weight loss.
**Synergistic Metabolic Effects**
The dual agonist design of survodutide is engineered so that the GLP-1 component counterbalances glucagon's potential to raise blood glucose levels. Whilst glucagon stimulates hepatic glucose output, concurrent GLP-1-mediated insulin secretion helps to maintain euglycaemia. This careful balance allows patients to benefit from glucagon's energy-expenditure-enhancing and lipid-oxidising properties without experiencing clinically significant hyperglycaemia.
**Cardiovascular and Hepatic Pathways**
Emerging research suggests that survodutide's dual mechanism may also confer benefits on cardiovascular risk markers, including improvements in lipid profiles, reductions in inflammatory biomarkers, and potential effects on blood pressure. The hepatic effects are of particular interest, as clinical data have demonstrated significant reductions in liver fat and improvements in markers of liver fibrosis.
[Molecular Structure Diagram Placeholder]
Researched Benefits
Based on preclinical and clinical research findings:
- 1Significant body weight reduction, with clinical trials reporting mean weight loss exceeding 18% of baseline body weight over 46 weeks
- 2Substantial reduction in liver fat content, with studies showing over 80% of participants achieving clinically meaningful decreases in hepatic steatosis
- 3Improvements in glycaemic control including reduced HbA1c levels and enhanced insulin sensitivity
- 4Favourable changes in lipid profiles including reductions in triglycerides and LDL cholesterol
- 5Potential resolution of metabolic dysfunction-associated steatohepatitis (MASH) with improvement in fibrosis markers
- 6Reduction in waist circumference and visceral adiposity beyond that attributable to overall weight loss
- 7Improvements in cardiovascular risk markers including blood pressure and inflammatory biomarkers
- 8Enhanced energy expenditure through glucagon-mediated thermogenic effects, potentially supporting sustained weight management
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | Dose escalation from 0.3 mg to a target dose of up to 4.8 mg (clinical trial protocols have used stepwise escalation over several weeks to improve tolerability) |
| Frequency | Once weekly subcutaneous injection |
| Duration | Clinical trials have evaluated treatment periods of 46 weeks and longer; duration in clinical practice would be determined by prescribers |
| Notes | These protocols are based on published clinical trial designs and are not prescriptive recommendations. Survodutide is an investigational compound not approved for human use. Dose escalation schedules in trials typically involve 4-week intervals at each dose level to minimise gastrointestinal side effects. Always consult a qualified healthcare professional. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (sole route investigated in clinical trials)
| Half-Life | Stability |
|---|---|
| Approximately 60-70 hours, supporting once-weekly dosing based on clinical pharmacokinetic data | Supplied as a solution for injection in pre-filled devices in clinical trial settings; storage requirements typically 2-8°C as per investigational product handling guidelines |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Nausea, particularly during dose escalation phases (most frequently reported adverse event)
- Vomiting, generally mild to moderate and decreasing with continued treatment
- Diarrhoea, occurring more frequently at higher doses
- Decreased appetite (related to mechanism of action)
- Injection site reactions including erythema and pruritus
- Constipation reported in some participants
Rare Risks & Concerns
- Acute pancreatitis (theoretical class risk shared with GLP-1 receptor agonists)
- Cholelithiasis (gallstones) associated with rapid weight loss
- Potential hepatic effects requiring monitoring given glucagon receptor activation
- Hypoglycaemia, particularly if combined with insulin or sulphonylureas
Contraindications
- Personal or family history of medullary thyroid carcinoma (theoretical class precaution for GLP-1 agonists)
- Multiple endocrine neoplasia syndrome type 2 (MEN 2)
- Pregnancy and breastfeeding (no safety data available; contraindicated in clinical trials)
- Severe hepatic impairment (limited data)
- Known hypersensitivity to survodutide or any excipients
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not approved by the MHRA. Currently an investigational compound in Phase 3 clinical trials.
🇪🇺 European Union
Not authorised by the European Medicines Agency. Phase 3 clinical development ongoing.
Survodutide is being evaluated in multiple Phase 3 clinical trials including the SYNCHRONIZE programme for obesity and the SYMPHONY programme for MASH. Regulatory submissions are anticipated pending completion of pivotal trials. The compound has received Fast Track designation from the FDA for MASH.
Clinical Studies Summary
Survodutide Phase 2 Trial in Obesity: Dose-Ranging Efficacy and Safety
A randomised, double-blind, placebo-controlled Phase 2 trial evaluating multiple doses of survodutide in adults with obesity. The highest dose group achieved mean body weight reductions of approximately 18.7% over 46 weeks, with a dose-dependent response observed across all treatment arms.
Lancet. 2024;403(10427):529-540View on PubMed
Survodutide in Metabolic Dysfunction-Associated Steatohepatitis: Phase 2 Results
Phase 2 trial demonstrating that survodutide significantly reduced liver fat content and improved histological markers of MASH. Over 80% of participants in the higher dose groups achieved a reduction in liver fat of at least 30%, with notable improvements in fibrosis scores.
N Engl J Med. 2024;391(12):1112-1123View on PubMed
Pharmacokinetics and Pharmacodynamics of Survodutide in Healthy Volunteers
First-in-human study establishing the pharmacokinetic profile of survodutide, demonstrating a half-life supporting weekly dosing and dose-proportional exposure across the tested range. The study confirmed target engagement at both glucagon and GLP-1 receptors.
Clin Pharmacol Ther. 2022;112(4):891-900View on PubMed
Dual Glucagon/GLP-1 Receptor Agonism: Rationale and Metabolic Effects
Comprehensive review examining the scientific rationale behind dual glucagon/GLP-1 receptor agonism, including survodutide's mechanism of action and its differentiation from pure GLP-1 agonists. Discussed the potential advantages for hepatic fat reduction and energy expenditure.
Nat Rev Endocrinol. 2023;19(8):471-485View on PubMed
Looking for Survodutide?
Source research-grade Survodutide from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Related Peptides
Semaglutide
A GLP-1 receptor agonist approved for type 2 diabetes and obesity treatment, representing one of the most significant advances in weight management pharmacotherapy.
Learn moreLiraglutide
An earlier GLP-1 receptor agonist approved for diabetes and weight management, offering once-daily dosing with proven efficacy and safety.
Learn moreSemaglutide
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, representing a breakthrough in metabolic medicine with average weight loss of 15-17% in clinical trials.
Learn moreTirzepatide
A first-in-class dual GLP-1 and GIP receptor agonist achieving unprecedented weight loss of up to 22% in clinical trials, approved for type 2 diabetes and obesity treatment.
Learn moreRetatrutide
An investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, showing unprecedented weight loss of up to 24% in Phase 2 trials—potentially the most potent obesity treatment in development.
Learn more